SCHEMBL22015388

SCHEMBL22015388

CCCNC(=O)CCNC(=O)CNC(=O)CNC(=O)CNC(=O)CCCN1C(=O)CC(C(C)C)C1=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 1/20 0.39
HDAC4 P56524 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC7 Q8WUI4 1/20 0.39
HDAC2 Q92769 1/20 0.39
HDAC10 Q969S8 1/20 0.39
HDAC11 Q96DB2 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
HDAC9 Q9UKV0 1/20 0.39
HDAC5 Q9UQL6 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.37
HPGD P15428 1/20 0.37
HTT P42858 1/20 0.37
MEN1 O00255 4/20 0.35
KMT2A Q03164 4/20 0.35
CYP2C19 P33261 2/20 0.35
CNR1 P21554 1/20 0.33
KDM4E B2RXH2 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25964475 0.94 SMN1; SMN2 (0.44) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL18389703 0.93 HDAC3 (0.40) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL20420480 0.90 HDAC3 (0.40) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL19656388 0.90 HDAC3 (0.38) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL12700804 0.90 HDAC6 (0.39) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL18466109 0.89 HDAC6 (0.39) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL18389729 0.89 HDAC3 (0.42) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL22064399 0.89 HDAC3 (0.36) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL18466423 0.88 HDAC3 (0.38) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL18389748 0.88 HDAC3 (0.36) HDAC3HDAC4HDAC1HDAC7HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240216521-A1 METHODS OF PREPARING CELL-BINDING AGENT-DRUG CONJUGATES IMMUNOGEN INC (US) 2024-07-04 US disclosed
US-11833214-B2 Methods of preparing cell-binding agent-drug conjugates IMMUNOGEN, INC. (US) 2023-12-05 US disclosed
US-20200405874-A1 METHODS OF PREPARING CELL-BINDING AGENT-DRUG CONJUGATES IMMUNOGEN, INC. 2020-12-31 US disclosed
US-10822313-B2 Selective sulfonation of benzodiazepine derivatives IMMUNOGEN, INC. (US) 2020-11-03 US disclosed
US-20200157056-A1 SELECTIVE SULFONATION OF BENZODIAZEPINE DERIVATIVES IMMUNOGEN, INC. 2020-05-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11833214-B2 Methods of preparing cell-binding agent-drug conjugates EPCAM, CD2BP2, XPA HDAC3 3568/4885HDAC4 3867/4885HDAC1 3552/4885
US-20200405874-A1 METHODS OF PREPARING CELL-BINDING AGENT-DRUG CONJUGATES EPCAM, CD2BP2, XPA HDAC3 3568/4885HDAC4 3867/4885HDAC1 3552/4885
US-20240216521-A1 METHODS OF PREPARING CELL-BINDING AGENT-DRUG CONJUGATES EPCAM, CD2BP2, XPA HDAC3 3568/4885HDAC4 3867/4885HDAC1 3552/4885
US-10822313-B2 Selective sulfonation of benzodiazepine derivatives GABRA2, GABRA4, GABRA1 HDAC3 2216/4885HDAC4 3422/4885HDAC1 4112/4885
US-20200157056-A1 SELECTIVE SULFONATION OF BENZODIAZEPINE DERIVATIVES GABRA2, GABRA4, GABRA1 HDAC3 2216/4885HDAC4 3422/4885HDAC1 4112/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.